Sam Brusco, Associate Editor04.12.24
Bayer and Hologic began a first-of-its-kind collaboration to produce a coordinated solution for contrast-enhanced mammography (CEM). The duo will showcase the innovation at the annual Society of Breast Imaging Symposium.
CEM is a sensitive, relatively low-cost breast imaging modality that can help support breast cancer diagnosis and guide treatment. The offering merges Hologic’s mammography technologies and Bayer’s CEM contrast delivery system, the MEDRAD Stellant FLEX CT injection system—with the Certegra workstation, Bayer claims it’s the first and only CT injection system FDA 510(k) cleared with an additional CEM application.
By collaborating, Hologic and Bayer hope to streamline the purchasing process for radiologists and imaging facilities. The pair also aims to provide seamless setup and ongoing, supportive educational resources.
"We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”
The value of CEM as an adjunct to mammography has been affirmed by a rising number of independent scientific publications. CEM can be performed as part of everyday clinical practice and used in many clinical settings—including inconclusive clinical findings in previous imaging procedures.
CEM is a sensitive, relatively low-cost breast imaging modality that can help support breast cancer diagnosis and guide treatment. The offering merges Hologic’s mammography technologies and Bayer’s CEM contrast delivery system, the MEDRAD Stellant FLEX CT injection system—with the Certegra workstation, Bayer claims it’s the first and only CT injection system FDA 510(k) cleared with an additional CEM application.
By collaborating, Hologic and Bayer hope to streamline the purchasing process for radiologists and imaging facilities. The pair also aims to provide seamless setup and ongoing, supportive educational resources.
"We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”
The value of CEM as an adjunct to mammography has been affirmed by a rising number of independent scientific publications. CEM can be performed as part of everyday clinical practice and used in many clinical settings—including inconclusive clinical findings in previous imaging procedures.